Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD0156 · 1 trial · 1 indication
Safety and tolerability of AZD0156 alone or in combination with either olaparib, cytotoxic chemotherapies, or novel anti-cancer agents as assessed through collection of Adverse Event, Serious Adverse Event, Clinical Chemistry/Haematology/Coagulation/Vital Signs and ECG
| Arm | Type | Description |
|---|---|---|
| Safety and Tolerability | EXPERIMENTAL | All patients will receive AZD0156 as a monotherapy or in combination with either olaparib, cytotoxic chemotherapies, or novel anti-cancer agents to assess safety and tolerability |
| Name | Type | Description |
|---|---|---|
| AZD0156 | DRUG | All patients will receive AZD0156 as a monotherapy or in combination to assess safety and tolerability. |
| Olaparib | DRUG | Module 1 combination with olaparib |
| irinotecan | DRUG | Module 2 combination with irinotecan/FOLFIRI |
| Fluorouracil | DRUG | Module 2 combination with irinotecan/FOLFIRI |
| Folinic Acid | DRUG | Module 2 combination with irinotecan/FOLFIRI |
Inclusion criteria for all parts of the study * Confirmation of locally advanced/metastatic cancer. Refractory or resistant to standard therapy, or have no effective standard * Aged at least 18 yrs * Reasonable health (performance status 0 or 1), stable over the previous 2 weeks * Females who can h...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
AZD0156 is an investigational small molecule being studied for the treatment of advanced solid tumours. It is an oncology drug currently in clinical development, and it is not approved for any use.
AZD0156 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN.
AZD0156 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy.
AZD0156 has been studied in a Phase 1 clinical trial with the identifier NCT02588105. This trial assessed the safety and preliminary efficacy of AZD0156 at increasing doses, alone or in combination with other anti-cancer treatments, in patients with advanced cancer.
AZD0156 is the drug name used in clinical trials. No alternative names have been reported for this investigational agent.